IntroductionDiffuse midline glioma (DMG) remains one of the most aggressive and devastating brain tumors in children and young adults. Surgical removal is often impossible due to its deep-seated midli...
Diffuse midline glioma (DMG), specifically the H3K27-mutated subtype, is among the most malignant and lethal types of pediatric-type brain tumors. Marked by poor prognosis and ineffectiveness to tradi...
Introduction In a stunning surprise that has stunned the international biotech industry, a tiny and micro business in Tianjin, China, has come up with an anti-cancer medication that just won official...
Gliomas IntroductionBrain gliomas, especially aggressive types such as glioblastoma multiforme (GBM), have long been extremely challenging to treat because of their insensitivity to traditional therap...
Introduction Chimeric Antigen Receptor (CAR) T-cell therapy has already transformed the landscape of cancer treatment. Now, the 4th generation CAR T-cell therapy, augmented with interleukin-15 (IL-15...
On April 11, 2025, the Food and Drug Administration sanctioned nivolumab (Opdivo, Bristol Myers Squibb Company) in conjunction with ipilimumab (Yervoy, Bristol Myers Squibb Company) for the first trea...
On April 8, 2025, the Food and Drug Administration approved nivolumab (Opdivo, Bristol Myers Squibb Company) and ipilimumab (Yervoy, Bristol Myers Squibb Company) for adults and children 12 years and ...
On March 28, 2025, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) to be used with gemcitabine and cisplatin as a first treatment, followed by durvalumab alone as a follow-...
On March 28, 2025, the Food and Drug Administration expanded the use of lutetium Lu 177 vipivotide tetraxetan (Pluvicto, Novartis Pharmaceuticals Corporation) to include adults with prostate-specific ...
On March 26, 2025, the Food and Drug Administration sanctioned cabozantinib (Cabometyx, Exelixis, Inc.) for adult and pediatric patients aged 12 and older with previously treated, unresectable, locall...